Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 681.25% | Roth MKM | → $7 | Initiates Coverage On | → Buy |
| 06/07/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 04/18/2023 | 681.25% | Oppenheimer | $12 → $7 | Maintains | Outperform |
| 03/10/2022 | 2132.14% | Oppenheimer | $30 → $20 | Maintains | Outperform |
| 12/07/2021 | 3248.21% | Aegis Capital | → $30 | Initiates Coverage On | → Buy |
| 05/26/2021 | 4922.32% | Cantor Fitzgerald | → $45 | Initiates Coverage On | → Overweight |
| 05/07/2021 | 4587.5% | Oppenheimer | → $42 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2023 年 6 月 10 日 | 681.25% | Roth MKM | → 7 美元 | 启动覆盖范围开启 | → 购买 |
| 06/07/2023 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 04/18/2023 | 681.25% | 奥本海默 | 12 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 03/10/2022 | 2132.14% | 奥本海默 | 30 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 2021 年 7 月 12 日 | 3248.21% | 宙斯盾资本 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 5 月 26 日 | 4922.32% | 坎托·菲茨杰拉德 | → 45 美元 | 启动覆盖范围开启 | → 超重 |
| 05/07/2021 | 4587.5% | 奥本海默 | → 42 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics（CMMB）的目标价格是多少？
The latest price target for Chemomab Therapeutics (NASDAQ: CMMB) was reported by Roth MKM on October 6, 2023. The analyst firm set a price target for $7.00 expecting CMMB to rise to within 12 months (a possible 681.25% upside). 3 analyst firms have reported ratings in the last year.
Roth MKM于2023年10月6日公布了Chemomab Therapeutics（纳斯达克股票代码：CMMB）的最新目标股价。该分析公司将目标股价定为7.00美元，预计CMMB将在12个月内上涨至681.25％（可能上涨681.25％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics（CMMB）的最新分析师评级是多少？
The latest analyst rating for Chemomab Therapeutics (NASDAQ: CMMB) was provided by Roth MKM, and Chemomab Therapeutics initiated their buy rating.
Chemomab Therapeutics（纳斯达克股票代码：CMMB）的最新分析师评级由Roth MKM提供，Chemomab Therapeutics启动了买入评级。
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics（CMMB）的下一份分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Chemomab Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Chemomab Therapeutics的最后一次评级是在2023年10月6日提交的，因此你应该预计下一个评级将在2024年10月6日左右公布。
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
分析师对Chemomab Therapeutics（CMMB）的评级是否正确？
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a initiated with a price target of $0.00 to $7.00. The current price Chemomab Therapeutics (CMMB) is trading at is $0.90, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Chemomab Therapeutics（CMMB）评级最初的目标价为0.00美元至7.00美元。Chemomab Therapeutics（CMMB）目前的交易价格为0.90美元，在分析师的预测区间内。